Vor Biopharma Inc. 8-K

What Happened
Vor Biopharma Inc. filed an 8-K on January 2, 2026 announcing that Chief Development Officer Dr. Qing Zuraw’s employment ended on December 31, 2025 under a Separation Agreement. The Separation Agreement provides severance benefits consistent with Dr. Zuraw’s July 17, 2025 employment agreement (as amended November 2, 2025) for any resignation between December 31, 2025 and April 2, 2026. The agreement also contains a general release of claims, a 12‑month non‑compete, and customary non‑disparagement and confidentiality covenants. The company expects to engage Dr. Zuraw as a consultant to assist with transition matters in the first quarter of 2026. The full Separation Agreement is filed as Exhibit 10.1 to the 8‑K.

Key Details

• Executive: Dr. Qing Zuraw, Chief Development Officer — employment ended December 31, 2025.
• Severance/terms: Severance protections apply per the July 17, 2025 Employment Agreement (amended Nov 2, 2025) for resignations through April 2, 2026.
• Restrictions: Separation includes a 12‑month non‑compete plus non‑disparagement and confidentiality obligations.
• Transition: Company anticipates a consulting arrangement with Dr. Zuraw in Q1 2026 to support transition.

Why It Matters
Management changes at the senior development level can affect clinical program continuity and timelines, so investors should note leadership turnover in R&D. Vor has structured an orderly exit with severance and an expected consulting arrangement to support transition, and the non‑compete may limit Dr. Zuraw’s immediate involvement with competitors. The filing does not disclose monetary severance amounts or a named replacement, so investors may want to watch for further disclosures about any successor, potential one‑time severance expenses, or impacts on development programs.